Merck KGaA Expands Biotech Production Capacity in Spain
A €15-million investment will be made over 2014-2016 in a biotech facility located in Tres Cantos, Spain
On Oct. 17, 2016, Merck KGaA, Darmstadt, Germany, announced the expansion of its biotech plant in Tres Cantos, Madrid, Spain, resulting in a 50% increase in the facility’s production capacity. Tres Cantos is Merck KGaA’s main site for the production of the active substances of its fertility treatment Gonal-f and growth hormone disorders treatment Saizen.
Extension of manufacturing plant will help meet worldwide demand for fertility and growth hormone disorder treatments, the company said in a statement. The €15-million (approximately $16.49) investment, which was made over the 2014–2016 period, adds 900 m2 of biotech production space and a two-floor office building, bringing the total constructed area of the Tres Cantos site to 8000 m2. The facility complies with the international cGMP quality standards. It is certified by ISO 14001 environmental management and safety by OHSAS 18001. The site employs 170 highly qualified professionals.
Source: Merck KGaA
